ScreenerHero
CLNCelon Pharma S.A.
GPW · PL · Healthcare · Drug Manufacturers - Specialty & Generic · celonpharma.com
22.60PLN+0.44%Mkt Cap: 222.72M $P/E: 11.08

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap222.72M $
Enterprise Value318.19M $
Revenue (TTM)64.43M $
Gross Profit47.88M $
Net Income (TTM)-20.10M $
Revenue/Share1.213 USD
Last Price22.60 PLN
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees564
CountryPL
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINPLCLNPH00015
Valuation
P/E (Trailing)11.08
P/E (Forward)14.16
PEG—
EV/EBITDA65.59
EV/Revenue4.94
P/S3.46
P/B2.31
EPS (TTM)2.04
EPS (Forward)1.60
52W Range
18.5082% of range23.50
52W High23.50 PLN
52W Low18.50 PLN
Profitability
Gross Margin74.32%
Oper. Margin-9.75%
EBITDA Margin7.53%
Profit Margin42.58%
ROE-21.85%
ROA-17.35%
Growth
Revenue Growth24.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF6.04M $
CapEx (TTM)—
FCF Margin-9.82%
FCF Yield-2.84%
Net Debt11.29M $
Net Debt/EBITDA2.33
Balance Sheet
Debt/Equity10.15
Current Ratio1.20
Quick Ratio0.87
Book Value/Sh9.818 PLN
Cash/Share0.1690 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield0.68%
Payout Ratio0.00%
Ex-Div DateJun 27, 2024
Pay Date—
Analyst Consensus
Rating—
Target (Mean)20.44 PLN
Upside (mean)-9.6%
Target Range16.00 PLN – 25.50 PLN
PLN16.00-9.6% to meanPLN25.50
# Analysts5
Ownership
Shares Out.38.91M
Float23.82M
Insiders55.70%
Institutions18.36%
Technical
SMA 5020.36 (+11.0%)
SMA 20020.97 (+7.8%)
Beta0.62
S&P 52W Chg18.16%
Avg Vol (30d)14.10K
Avg Vol (10d)6.55K
Technical Indicators
RSI (14)74.4
MACD0.1788
MACD Signal0.0975
MACD Hist.+0.0813
BB Upper21.67 PLN
BB Middle20.78 PLN
BB Lower19.89 PLN
BB Width8.57%
ATR (14)0.6439 PLN
Vol Ratio (20d)18.08x